Cargando…
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826846/ https://www.ncbi.nlm.nih.gov/pubmed/31614574 http://dx.doi.org/10.3390/brainsci9100272 |
_version_ | 1783465187877060608 |
---|---|
author | Martí-Andrés, Gloria Jiménez-Bolaños, Rayco Arbelo-González, José Matias Pagonabarraga, Javier Duran-Herrera, Carmen Valenti-Azcarate, Rafael Luquin, Mª Rosario |
author_facet | Martí-Andrés, Gloria Jiménez-Bolaños, Rayco Arbelo-González, José Matias Pagonabarraga, Javier Duran-Herrera, Carmen Valenti-Azcarate, Rafael Luquin, Mª Rosario |
author_sort | Martí-Andrés, Gloria |
collection | PubMed |
description | Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control. |
format | Online Article Text |
id | pubmed-6826846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68268462019-11-18 Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study Martí-Andrés, Gloria Jiménez-Bolaños, Rayco Arbelo-González, José Matias Pagonabarraga, Javier Duran-Herrera, Carmen Valenti-Azcarate, Rafael Luquin, Mª Rosario Brain Sci Article Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). Methods: A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. Furthermore, we assessed the appearance of adverse events (AEs) and its effect on dyskinesia, that were also recorded in non-fluctuating PD patients and in those previously treated with rasagiline. Results: We included 213 PD patients who received safinamide in addition to their regular levodopa therapy. Thirty-five withdrew prematurely from safinamide, mainly because of AEs. Out of 178, clinical improvement on motor and NMS was found in 76.4% and 26.2%, respectively. A total of 44 reported AEs of mild intensity. We did not find a difference concerning the clinical benefit or AEs when comparing either patients who had or had not been taking Monoamine Oxidase B Inhibitor (MAOB-I) previously or between patients with and without motor complications. Conclusions: Safinamide is an effective and safe add-on to levodopa drug for PD patients. Moreover, safinamide could elicit an additional clinical improvement in PD patients previously treated with other MAOB-I and in non- fluctuating patients with suboptimal motor control. MDPI 2019-10-11 /pmc/articles/PMC6826846/ /pubmed/31614574 http://dx.doi.org/10.3390/brainsci9100272 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Martí-Andrés, Gloria Jiménez-Bolaños, Rayco Arbelo-González, José Matias Pagonabarraga, Javier Duran-Herrera, Carmen Valenti-Azcarate, Rafael Luquin, Mª Rosario Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title | Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title_full | Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title_fullStr | Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title_full_unstemmed | Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title_short | Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study |
title_sort | safinamide in clinical practice: a spanish multicenter cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826846/ https://www.ncbi.nlm.nih.gov/pubmed/31614574 http://dx.doi.org/10.3390/brainsci9100272 |
work_keys_str_mv | AT martiandresgloria safinamideinclinicalpracticeaspanishmulticentercohortstudy AT jimenezbolanosrayco safinamideinclinicalpracticeaspanishmulticentercohortstudy AT arbelogonzalezjosematias safinamideinclinicalpracticeaspanishmulticentercohortstudy AT pagonabarragajavier safinamideinclinicalpracticeaspanishmulticentercohortstudy AT duranherreracarmen safinamideinclinicalpracticeaspanishmulticentercohortstudy AT valentiazcaraterafael safinamideinclinicalpracticeaspanishmulticentercohortstudy AT luquinmarosario safinamideinclinicalpracticeaspanishmulticentercohortstudy |